Dendreon Corporation, a biotechnology company, focuses on the discovery, development, and commercialization of novel therapeutics that might improve cancer treatment options for patients. The company’s product portfolio includes active cellular immunotherapies and a small molecule product candidate that could be applicable to treating multiple types of cancers. Products PROVENGE (sipuleucel-T) PROVENGE (sipuleucel-T) is the company’s first commercialized product approved by the United States Food and Drug Administration and is an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic, metastatic, castrate-resistant (hormone-refractory) prostate cancer. The company owns worldwide rights for PROVENGE. Others The company’s other product candidates under development include its investigational active cellular immunotherapy, DN24-02, which might be used to treat solid tumors expressing HER2/neu, such as bladder, breast, and ovarian. Active cellular immunotherapies directed at carbonic anhydrase 9, an antigen expressed in renal cell carcinoma, and carcinoembryonic antigen, an antigen expressed in colorectal and other cancers, are in preclinical development. The company is also investigating further development of an orally-available small molecule targeting TRPM8 that could be applicable in treating multiple types of cancer. The company completed its Phase 1 clinical trial in 2012 to evaluate TRPM8. Suppliers The company’s supplier includes Fujifilm Diosynth Biotechnologies. Intellectual Property The company has three issued United States patents with claims relating to immunostimulatory compositions, including PROVENGE, and to methods of treating specific diseases, including prostate cancer, using the immunostimulatory compositions. It also has four issued United States patents with claims relating to the cell separation devices and related media and certain aspects of the manufacturing process used to produce PROVENGE. The scheduled expiration dates of its United States patents related to PROVENGE are in 2014 through 2018. Outside the United States, the company has, in certain territories, corresponding issued patents related to PROVENGE that are scheduled to expire in 2015 through 2019. Regulatory The company is subject to regulation by the Occupational Safety and Health Administration, and the Environmental Protection Agency, and to regulation under the Toxic Substances Control Act, the Resource Conservation and Recovery Act and other regulatory statutes, and might in the future be subject to other federal, state, or local regulations. Trademarks and Tradenames Dendreon, the Dendreon logo, Dendreon Targeting Cancer, Transforming Lives, PROVENGE, NEUVENGE, INTELLIVENGE, Powered by Intellivenge, and Antigen Delivery Cassette are the company’s trademarks. History Dendreon Corporation, a Delaware corporation, was founded in 1992.